Regencell Bioscience Holdings Limited (RGC)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Regencell Bioscience Holdings Limited (RGC) is up 13.1% since the beginning of the year. At $24 per share, RGC is trading 71.6% below its 52-week high of $84.

Regencell Bioscience Holdings Limited (RGC) has returned 13.10% so far this year and 48.17% over the past 12 months.

Based on dividend-adjusted daily data since Jul 16, 2021, RGC's average daily return is +1.34%, while the average monthly return is +39.10%. At this rate, an investment would double in approximately 0.2 years.

Historically, 47% of months were positive and 53% were negative. The best month was May 2025 with a return of +1,361.7%, while the worst month was Mar 2022 at -40.9%. The longest winning streak lasted 4 consecutive months, and the longest losing streak was 5 months.

On a daily basis, RGC closed higher 38% of trading days. The best single day was Jul 23, 2024 with a return of +343.9%, while the worst single day was Jun 20, 2025 at -40.0%.

Regencell Bioscience Holdings Limited has an annualized alpha of 2648.99%, beta of 0.40, and R2 of 0.00 versus S&P 500 Index. Calculated based on daily prices since July 19, 2021.

• This stock captured 49.08% of S&P 500 Index gains and tended to rise during its downturns (downside capture of -1596.31%) - a profile typical of hedging or uncorrelated assets.
• Beta of 0.40 may look defensive, but with R2 of 0.00 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R2 of 0.00 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

RGC ranks 66 for risk / return — better than 66% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The table below present risk-adjusted performance metrics for Regencell Bioscience Holdings Limited (RGC) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Regencell Bioscience Holdings Limited. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Regencell Bioscience Holdings Limited was 93.09%, occurring on Jul 16, 2024. Recovery took 171 trading sessions.

The current Regencell Bioscience Holdings Limited drawdown is 69.55%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Regencell Bioscience Holdings Limited over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Regencell Bioscience Holdings Limited is priced in the market compared to other companies in the Drug Manufacturers - Specialty & Generic industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.